Amlodipine is a medication used to treat high blood pressure and certain types of angina (chest pain). It is a type of calcium channel blocker, which means it works by relaxing the blood vessels, making it easier for the heart to pump blood around the body. Amlodipine is usually taken once a day in tablet form, with or without food. The dosage will depend on the individual and their medical condition. It's important to take the medication exactly as prescribed by a healthcare professional, and not to stop taking it without consulting a doctor.
Amlodipine is a widely used medication for the treatment of hypertension (high blood pressure) and angina. It is available under various brand names, including Norvasc, Istin, and Amloc, among others. Amlodipine is a relatively inexpensive medication and is available in both generic and brand-name forms. Amlodipine is one of the most commonly prescribed medications for the treatment of hypertension. It is included in the World Health Organization's List of Essential Medicines, which is a list of the most important medications needed in a basic health system.
Hypertension is a complex condition,
that often requires multiple medications to achieve optimal blood pressure control. Amlodipine is commonly used in combination with other medications, such as ACE inhibitors or ARBs, to achieve better blood pressure control in patients with hypertension. ACE inhibitors and ARBs work by blocking the action of the hormone angiotensin II, which can cause blood vessels to constrict and blood pressure to rise. Amlodipine works by relaxing the blood vessels, making it easier for the heart to pump blood around the body. When used in combination, these medications can work synergistically to lower blood pressure and reduce the risk of complications associated with hypertension.
The growing use of combination therapies for the treatment of hypertension is expected to drive the demand for amlodipine. In recent years, there has been a shift towards using combination therapies earlier in the course of treatment, rather than waiting until blood pressure is difficult to control with a single medication. This is because combination therapies can provide better blood pressure control and reduce the risk of complications associated with hypertension. In addition to ACE inhibitors and ARBs, amlodipine is also commonly used in combination with diuretics, beta-blockers, and other medications to achieve better blood pressure control. The increasing use of these combination therapies is expected to drive the demand for amlodipine, which is a commonly used medication in these regimens. Overall, the growing use of combination therapies for the treatment of hypertension is a significant driver of the demand for amlodipine, and this trend is expected to continue as healthcare providers and patients seek to achieve better blood pressure control and reduce the risk of complications associated with hypertension.
Furthermore, amlodipine is a relatively inexpensive medication compared to many other medications used to treat hypertension. This makes it an attractive option for both healthcare providers and patients, as it can help keep healthcare costs down while still providing effective treatment for hypertension. As healthcare costs continue to rise, the cost-effectiveness of amlodipine is expected to drive its continued use. Healthcare providers are under increasing pressure to provide cost-effective treatments, and amlodipine is often one of the first-line medications used to treat hypertension due to its cost-effectiveness. In addition to being cost-effective, amlodipine is also widely available in both generic and brand-name forms, which can further help to reduce costs for patients and healthcare providers. The availability of a generic form of a medication can often help to drive down the overall cost of treatment, making it more affordable for patients and healthcare systems.
New product launches to flourish in the marketIn 2020, Lupin Pharmaceuticals launched a new amlodipine and olmesartan medoxomil combination tablet, which is used to treat hypertension. In 2019, Sandoz Inc. received approval from the FDA for its amlodipine and valsartan combination tablet, which is also used to treat hypertension. Also, in 2018, Torrent Pharmaceuticals launched a new amlodipine and telmisartan combination tablet, which is also used to treat hypertension.
Segment Overview: By Type: The amlodipine market is divided into 2.5mg tablets, 5mg tablets and 10mg tablets. The 2.5mg tablet strength is often used for patients who require a lower dose of amlodipine, such as the elderly or those who have other health conditions that may increase their sensitivity to the medication. The 5mg and 10mg tablet strengths are often used for patients who require a higher dose of amlodipine to achieve optimal blood pressure control. Different tablet strengths may also be used at different stages of treatment, as patients may start with a lower dose and then gradually increase to a higher dose if needed. For example, a patient may start with a 2.5mg tablet once daily and then increase to a 5mg or 10mg tablet if their blood pressure is not adequately controlled.
By Application: The amlodipine market is divided into high blood pressure and heart diseases. Amlodipine is primarily used for the treatment of high blood pressure (hypertension), which is a common condition that affects many people worldwide. Hypertension is a major risk factor for heart disease, stroke, and other cardiovascular diseases, so the use of amlodipine can help to reduce the risk of these conditions. While amlodipine is primarily indicated for the treatment of hypertension, it may also be used in the treatment of certain heart conditions, such as angina pectoris and coronary artery disease. In these cases, amlodipine is often used to improve blood flow to the heart and reduce the workload on the heart, which can help to reduce symptoms and improve overall cardiovascular health.
By Region: The Asia Pacific amlodipine market is one of the fastest-growing markets for amlodipine in the world. The market is expected to experience significant growth in the coming years due to several factors.
One of the primary reasons of growth in the Asia Pacific amlodipine market is the high prevalence of hypertension in the region. Hypertension is a major health concern in many countries of the Asia Pacific region, and its prevalence is expected to increase in the coming years due to factors such as aging populations and changing lifestyles. Amlodipine is an effective and commonly used medication for the treatment of hypertension, which is expected to drive/ increase the demand for the drug in the region.
Another factor driving the growth of the Asia Pacific amlodipine market is the increasing availability and affordability of healthcare in the region. As healthcare infrastructure improves and access to medical services becomes more widespread, more patients are able to receive a diagnosis of hypertension and access treatment with medications like amlodipine. The growing awareness of hypertension and its associated risks is also expected to contribute to the growth of the amlodipine market in the Asia Pacific region. As more people become aware of the importance of managing blood pressure and reducing the risk of heart disease and other cardiovascular conditions, the demand for medications like amlodipine is likely to increase.
Competitive analysis and profiles of the major players in the amlodipine market, such as Aurobindo Pharma Ltd,. Epic Pharma, Macleods Pharmaceuticals ltd., Pfizer Inc., Alkem Laboratories Ltd. Mylan N V, Dr. Reddy's, CR Pharmaceuticals , Cipla Ltd, Zydus Wellness Ltd, and Tianjin Chasesun Pharmaceutical Co., Ltd are included in the report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the amlodipine market.
Key Market Segments
- By Type
- 2.5mg Tablets
- 5mg Tablets
- 10mg Tablets
- By Application
- High Blood Pressure
- Heart Diseases
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Malaysia
- Indonesia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- UAE
- Argentina
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- Aurobindo Pharma Ltd
- CR Pharmaceutical
- Dr. Reddy's
- Tianjin Chasesun Pharmaceutical Co., Ltd
- epic pharma
- Cipla Ltd
- Alkem Laboratories Ltd
- macleods pharmaceuticals ltd.
- Zydus Wellness Ltd
- Mylan Nv